ADRX-0405

N/A

Report date: 2026/03/31 20:00:21
First In Class

Base Information

Drug NameADRX-0405
Drug Alias NameADRX-0405
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker
Mechanisms of ActionDNA topoisomerase inhibitorsAnti-STEAP1
TargetsDNA topoisomeraseSix-transmembrane epithelial antigen of the prostate 1
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaIND
Originator CompaniesAdcentrx Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Defeng Pharmaceutical Co LtdAdcentrx Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A